OTHER × Hodgkin Disease × Bortezomib × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
NCT01164709 2019-05-15

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Swiss Cancer Institute

Phase 1 Completed
18 enrolled
NCT00237627 2012-05-18

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Completed
107 enrolled